Unresectable hepatocellular carcinoma : MR imaging after intraarterial therapy. part i. identification and validation of volumetric functional response criteria

Radiology

Volumn 268, Issue 2, 2013, Pages 420-430

  Bonekamp, Susanne ^a   Li, Zhen ^a,c   Geschwind, Jean François H ^a   Halappa, Vivek Gowdra ^a   Corona Villalobos, Celia Pamela ^a   Reyes, Diane ^a   Pawlik, Timothy M ^b   Bonekamp, David ^a   Eng, John ^a   Kamel, Ihab R ^a  

^a Department of Surgery ^*  (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DOXORUBICIN; GADOLINIUM PENTETATE; SORAFENIB; YTTRIUM 90;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; DIFFUSION COEFFICIENT; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; TREATMENT RESPONSE;

ANALYSIS OF VARIANCE; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CHI-SQUARE DISTRIBUTION; CONTRAST MEDIA; DOXORUBICIN; FEMALE; GADOLINIUM DTPA; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84880693968     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.13122307     Document Type: Article

References (40)

1. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27(9):1485-1491.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60(5):277-300.
3. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37(2):429-442.
4. Cammà C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: Metaanalysis of randomized controlled trials. Radiology 2002;224(1):47-54.
5. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100(10):698-711.
6. Cabrera R, Nelson DR. Review article: The management of hepatocellular carcinoma. Aliment Pharmacol Ther 2010;31(4):461-476.
7. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva, Switzerland: World Health Organization, 1979.
8. Vilgrain V. Advancement in HCC imaging: Diagnosis, staging and treatment efficacy assessments: Hepatocellular carcinoma-imaging in assessing treatment efficacy. J Hepatobiliary Pancreat Sci 2010;17(4):374-379.
9. Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: Are response evaluation criteria in solid tumors reliable? Cancer 2009;115(3):616-623.
10. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001;35(3):421-430.
11. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30(1):52-60.
12. Suzuki C, Jacobsson H, Hatschek T, et al. Radiologic measurements of tumor response to treatment: Practical approaches and limitations. RadioGraphics 2008;28(2):329-344.
13. Suzuki C, Torkzad MR, Jacobsson H, et al. Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria. Acta Oncol 2010;49(4):509-514.
14. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-390.
15. Gulsun MA, Weiss CR, Strecker R, Meredith G, Kamel IR. A new tool for volumetric and functional analysis of hepatic tumors monitored with multi-modal MRI [abstr]. In: Proceedings of the Seventeenth Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 2009; 2876.
16. Wormanns D, Kohl G, Klotz E, et al. Volumetric measurements of pulmonary nodules at multi-row detector CT: In vivo reproducibility. Eur Radiol 2004;14(1):86-92.
17. Puesken M, Juergens KU, Edenfeld A, et al. Accuracy of liver lesion assessment using automated measurement and segmentation software in biphasic multislice CT (MSCT) [in German]. Rofo 2009;181(1):67-73.
18. Van Hoe L, Van Cutsem E, Vergote I, et al. Size quantification of liver metastases in patients undergoing cancer treatment: Reproducibility of one-, two-, and three-dimensional measurements determined with spiral CT. Radiology 1997;202(3):671-675.
19. Zhao B, Schwartz LH, Moskowitz CS, Ginsberg MS, Rizvi NA, Kris MG. Lung cancer: Computerized quantification of tumor response-initial results. Radiology 2006;241(3):892-898.
20. Moffat BA, Chenevert TL, Lawrence TS, et al. Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A 2005;102(15):5524-5529.
21. Bonekamp S, Jolepalem P, Lazo M, Gulsun MA, Kiraly AP, Kamel IR. Hepatocellular carcinoma: Response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrastenhanced MR imaging data. Radiology 2011;260(3):752-761.
22. Geschwind JF, Ramsey DE, Cleffken B, et al. Transcatheter arterial chemoembolization of liver tumors: Effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency. Cardiovasc Intervent Radiol 2003;26(2):111-117.
23. Reyes DK, Vossen JA, Kamel IR, et al. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: Initial experience in the United States. Cancer J 2009;15(6):526-532.
24. Li Z, Bonekamp S, Halappa VG, et al. Islet cell liver metastases: Assessment of volumetric early response with functional MR imaging after transarterial chemoembolization. Radiology 2012;264(1):97-109.
25. Halappa VG, Bonekamp S, Corona-Villalobos CP, et al. Intrahepatic cholangiocarcinoma treated with local-regional therapy: Quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response. Radiology 2012;264(1):285-294.
26. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-216.
27. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: A review of validation studies on tumour assessment. Eur J Cancer 2006;42(8):1031-1039.
28. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-247.
29. Atassi B, Bangash AK, Bahrani A, et al. Multimodality imaging following 90Y radioembolization: A comprehensive review and pictorial essay. RadioGraphics 2008;28(1):81-99.
30. Kim YS, Rhim H, Lim HK. Imaging after radiofrequency ablation of hepatic tumors. Semin Ultrasound CT MR 2009;30(2):49-66.
31. Kuszyk BS, Boitnott JK, Choti MA, et al. Local tumor recurrence following hepatic cryoablation: Radiologic-histopathologic correlation in a rabbit model. Radiology 2000;217(2):477-486.
32. Chalian H, Tochetto SM, Töre HG, Rezai P, Yaghmai V. Hepatic tumors: Region-ofinterest versus volumetric analysis for quantification of attenuation at CT. Radiology 2012;262(3):853-861.
33. Mannelli L, Kim S, Hajdu CH, Babb JS, Clark TW, Taouli B. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: Diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol 2009;193(4):1044-1052.
34. Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: Consensus and recommendations. Neoplasia 2009;11(2):102-125.
35. Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF. Unresectable hepatocellular carcinoma: Serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology 2009;250(2):466-473.
36. Kim S, Mannelli L, Hajdu CH, et al. Hepatocellular carcinoma: Assessment of response to transarterial chemoembolization with image subtraction. J Magn Reson Imaging 2010;31(2):348-355.
37. Memon K, Kulik L, Lewandowski RJ, et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 2011;141(2):526-535, 535.e1-e2.
38. Jin B, Wang D, Lewandowski RJ, et al. Chemoembolization endpoints: Effect on survival among patients with hepatocellular carcinoma. AJR Am J Roentgenol 2011;196(4):919-928.
39. Lewandowski RJ, Mulcahy MF, Kulik LM, et al. Chemoembolization for hepatocellular carcinoma: Comprehensive imaging and survival analysis in a 172-patient cohort. Radiology 2010;255(3):955-965.
40. Olivo M, Valenza F, Buccellato A, et al. Transcatheter arterial chemoembolisation for hepatocellular carcinoma in cirrhosis: Survival rate and prognostic factors. Dig Liver Dis 2010;42(7):515-519.